Form D · Pharmaceuticals
BIOXINESS PHARMACEUTICALS, INC.
Hercules, CA · CIK 0001470930
Offering snapshot reported Sep 21, 2016 · SEC filing
- Reported sold
- $502K Offering amount: $1M
- Investors reported
- 29 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 6, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 21, 2016 | Initial | $502,000 | No comparison | 29 | SEC filing |
| Jan 20, 2011 | Amendment | $302,568 | $217,568vs Sep 4, 2009 | 8 | SEC filing |
| Sep 4, 2009 | Initial | $85,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-271024
Conversion of convertible notes into equity
Source: Form D, filed Sep 21, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mansour Bassiri | Director, Executive, Promoter |
| Susan Froshauer | Director |
| Reza Ilkhani | Director, Executive |
| Matthew Kerby | Director |
| Constance Mc Kee | Director |
| Clint H. Severson | Director |
| Clinton Severson | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
750 Alfred Nobel Drive Suite 106
Hercules, CA, 94547
Hercules, CA, 94547